CN116875550B - 一种FABP4+C1q+巨噬细胞及其制备方法和用途 - Google Patents
一种FABP4+C1q+巨噬细胞及其制备方法和用途 Download PDFInfo
- Publication number
- CN116875550B CN116875550B CN202311155081.8A CN202311155081A CN116875550B CN 116875550 B CN116875550 B CN 116875550B CN 202311155081 A CN202311155081 A CN 202311155081A CN 116875550 B CN116875550 B CN 116875550B
- Authority
- CN
- China
- Prior art keywords
- fabp4
- macrophages
- macrophage
- tumor
- double
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000002540 macrophage Anatomy 0.000 title claims abstract description 93
- 102100030431 Fatty acid-binding protein, adipocyte Human genes 0.000 title claims abstract description 61
- 101001062864 Homo sapiens Fatty acid-binding protein, adipocyte Proteins 0.000 title claims abstract description 61
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 3
- 230000001024 immunotherapeutic effect Effects 0.000 claims abstract description 3
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 10
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 10
- 210000001616 monocyte Anatomy 0.000 claims description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 230000006698 induction Effects 0.000 claims description 5
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims description 4
- 239000011324 bead Substances 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 210000005259 peripheral blood Anatomy 0.000 claims description 4
- 239000011886 peripheral blood Substances 0.000 claims description 4
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 238000000432 density-gradient centrifugation Methods 0.000 claims description 2
- 239000002609 medium Substances 0.000 claims description 2
- 210000005087 mononuclear cell Anatomy 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 30
- 238000009169 immunotherapy Methods 0.000 abstract description 17
- 230000002757 inflammatory effect Effects 0.000 abstract description 16
- 230000016396 cytokine production Effects 0.000 abstract description 9
- 230000000242 pagocytic effect Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 210000001165 lymph node Anatomy 0.000 abstract description 6
- 201000011510 cancer Diseases 0.000 abstract description 4
- 230000000259 anti-tumor effect Effects 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 230000014509 gene expression Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 101100226596 Gallus gallus FABP gene Proteins 0.000 description 11
- 108020004459 Small interfering RNA Proteins 0.000 description 11
- 238000001890 transfection Methods 0.000 description 11
- 230000006870 function Effects 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 238000007789 sealing Methods 0.000 description 6
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 5
- 102100025136 Macrosialin Human genes 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 230000002452 interceptive effect Effects 0.000 description 4
- 229940100601 interleukin-6 Drugs 0.000 description 4
- 230000008782 phagocytosis Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000037956 transmissible mink encephalopathy Diseases 0.000 description 4
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 230000013227 macrophage apoptotic process Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- DHGBAFGZLVRESL-UHFFFAOYSA-N 14-methylpentadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C DHGBAFGZLVRESL-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101000588145 Homo sapiens Microtubule-associated tumor suppressor 1 Proteins 0.000 description 2
- 101000588157 Homo sapiens Microtubule-associated tumor suppressor candidate 2 Proteins 0.000 description 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 2
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 2
- 102100031549 Microtubule-associated tumor suppressor candidate 2 Human genes 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 101100514842 Xenopus laevis mtus1 gene Proteins 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 230000004133 fatty acid degradation Effects 0.000 description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 101150073133 Cpt1a gene Proteins 0.000 description 1
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 1
- 102000030914 Fatty Acid-Binding Human genes 0.000 description 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 1
- 101000841267 Homo sapiens Long chain 3-hydroxyacyl-CoA dehydrogenase Proteins 0.000 description 1
- 101000760730 Homo sapiens Medium-chain specific acyl-CoA dehydrogenase, mitochondrial Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102100029107 Long chain 3-hydroxyacyl-CoA dehydrogenase Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100024590 Medium-chain specific acyl-CoA dehydrogenase, mitochondrial Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108091022862 fatty acid binding Proteins 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 150000004665 fatty acids Chemical group 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000011022 opal Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000013138 pruning Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311155081.8A CN116875550B (zh) | 2023-09-08 | 2023-09-08 | 一种FABP4+C1q+巨噬细胞及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311155081.8A CN116875550B (zh) | 2023-09-08 | 2023-09-08 | 一种FABP4+C1q+巨噬细胞及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116875550A CN116875550A (zh) | 2023-10-13 |
CN116875550B true CN116875550B (zh) | 2023-12-26 |
Family
ID=88270296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311155081.8A Active CN116875550B (zh) | 2023-09-08 | 2023-09-08 | 一种FABP4+C1q+巨噬细胞及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116875550B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104302322A (zh) * | 2012-03-26 | 2015-01-21 | 日本化学药品株式会社 | 骨·软组织中产生的巨细胞性肿瘤或软骨肉瘤的预防或治疗剂 |
CN109071663A (zh) * | 2016-02-05 | 2018-12-21 | 奥里尼斯生物科学公司 | 双特异性信号传导剂及其用途 |
CN112805004A (zh) * | 2018-07-02 | 2021-05-14 | 艾珀特玛治疗公司 | 向人脂肪细胞靶向递送治疗剂 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107271675B (zh) * | 2017-03-24 | 2020-06-02 | 郑猛 | 抗人adrb3单克隆抗体及其在疾病诊断和治疗中的应用 |
US20200354424A1 (en) * | 2018-01-26 | 2020-11-12 | Orionis Biosciences, Inc. | Xcr1 binding agents and uses thereof |
JP2023523588A (ja) * | 2020-04-22 | 2023-06-06 | ダイレクト バイオロジクス エルエルシー | 感染疾患に関連する炎症状態を治療するための方法及び組成物 |
-
2023
- 2023-09-08 CN CN202311155081.8A patent/CN116875550B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104302322A (zh) * | 2012-03-26 | 2015-01-21 | 日本化学药品株式会社 | 骨·软组织中产生的巨细胞性肿瘤或软骨肉瘤的预防或治疗剂 |
CN109071663A (zh) * | 2016-02-05 | 2018-12-21 | 奥里尼斯生物科学公司 | 双特异性信号传导剂及其用途 |
CN112805004A (zh) * | 2018-07-02 | 2021-05-14 | 艾珀特玛治疗公司 | 向人脂肪细胞靶向递送治疗剂 |
Non-Patent Citations (1)
Title |
---|
Single-cell RNA datasets and bulk RNA datasets analysis demonstrated C1Q+ tumor-associated macrophage as a major and antitumor immune cell population in osteosarcoma;Jihao Tu;Front. Immunol;第14卷;1-11 * |
Also Published As
Publication number | Publication date |
---|---|
CN116875550A (zh) | 2023-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shimada et al. | Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma | |
Suzuki et al. | Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma | |
Ren et al. | Colon cancer cells secrete exosomes to promote self-proliferation by shortening mitosis duration and activation of STAT3 in a hypoxic environment | |
Liu et al. | THBS1 facilitates colorectal liver metastasis through enhancing epithelial–mesenchymal transition | |
CN108315414B (zh) | 一种预测食管鳞状细胞癌预后的生物标志物 | |
Kobawala et al. | Significance of interleukin-6 in papillary thyroid carcinoma | |
Zhao et al. | Database mining of genes of prognostic value for the prostate adenocarcinoma microenvironment using the cancer gene atlas | |
Zhang et al. | Human CD133-positive hematopoietic progenitor cells initiate growth and metastasis of colorectal cancer cells | |
Chen et al. | Implication of IL-17 producing ɑβT and γδT cells in patients with ovarian cancer | |
Xie et al. | Overexpression and clinical relevance of the RNA helicase DHX15 in hepatocellular carcinoma | |
Shan et al. | Granulocyte-macrophage colony-stimulating factor-activated neutrophils express B7-H4 that correlates with gastric cancer progression and poor patient survival | |
Walterskirchen et al. | Metastatic colorectal carcinoma-associated fibroblasts have immunosuppressive properties related to increased IGFBP2 expression | |
CN116875550B (zh) | 一种FABP4+C1q+巨噬细胞及其制备方法和用途 | |
Yang et al. | Liquid biopsy for ovarian cancer using circulating tumor cells: recent advances on the path to precision medicine | |
Feng et al. | Excessive activation of IL‑33/ST2 in cancer‑associated fibroblasts promotes invasion and metastasis in ovarian cancer | |
Yoshikawa et al. | Characterization of CD133+ parenchymal cells in the liver: Histology and culture | |
Li et al. | Expression of RAD51 and its clinical impact in oral squamous cell carcinoma | |
Wu et al. | RPL35A is a key promotor involved in the development and progression of gastric cancer | |
CN106676074B (zh) | 一种体外扩增肝癌干细胞的方法 | |
Sharma et al. | Myeloid‐derived suppressor cells: bridging the gap between inflammation and pancreatic adenocarcinoma | |
Li et al. | SHP-2-induced M2 polarization of tumor associated macrophages via IL-4 regulate colorectal cancer progression | |
Xu et al. | Human Umbilical Cord Mesenchymal Stem Cells-derived Exosomal lncRNA FAM99B Represses Hepatocellular Carcinoma Cell Malignancy | |
Yang et al. | BOP1 silencing suppresses gastric cancer proliferation through p53 modulation | |
Zhu et al. | C1QTNF6 overexpression acts as a predictor of poor prognosis in bladder cancer patients | |
Yan et al. | COL12A1 as a prognostic biomarker links immunotherapy response in breast cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: No. 47 Binshui Road, Huanhu West Road, Hexi District, Tianjin City, 300060 Applicant after: TIANJIN CANCER HOSPITAL(TIANJIN MEDICAL University CANCERINSTITUTE& Hospital) Applicant after: Cell Ecology Haihe Laboratory Address before: 2-1-101, Building 1-3, Bolong Industrial Park, north of Yuexin Road and east of Huixin Road, Binhai Science and Technology Park, Binhai High-tech Zone, Binhai New District, Tianjin 300450 Applicant before: Cell Ecology Haihe Laboratory Applicant before: TIANJIN CANCER HOSPITAL(TIANJIN MEDICAL University CANCERINSTITUTE& Hospital) |
|
GR01 | Patent grant | ||
GR01 | Patent grant |